Tessera Therapeutics Funding: $300M Raised, Series C (2022)
Tessera Therapeutics is based in Cambridge. It has raised $300M in total funding. Latest round: Series C.
Tessera Therapeutics funding overview
Tessera Therapeutics is based in Cambridge. Tessera Therapeutics has raised $300M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in April 2022. The round record for Tessera Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include Alaska Permanent Fund Corporation, Abu Dhabi Investment Authority. 2 distinct backers are named across the disclosed rounds.
Tessera Therapeutics at a glance
Total raised
$300M
Latest round
Series C
Latest round date
April 2022
Headquarters
Cambridge
Notable investors
Alaska Permanent Fund Corporation, Abu Dhabi Investment Authority
Frequently asked about Tessera Therapeutics funding
How much has Tessera Therapeutics raised?
Tessera Therapeutics has raised $300M in total disclosed funding across the rounds on record.
Who has invested in Tessera Therapeutics?
Alaska Permanent Fund Corporation, Abu Dhabi Investment Authority are named among the investors backing Tessera Therapeutics.
What was the latest Tessera Therapeutics funding round?
The most recent disclosed round is a Series C, announced in April 2022.
Where is Tessera Therapeutics based?
Tessera Therapeutics is based in Cambridge.
When did Tessera Therapeutics last raise?
The last disclosed Tessera Therapeutics round closed in April 2022 at Series C.
Round data for Tessera Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Cambridge and backer lists below.
